Atp Launches Adendra Therapeutics, A New Kind Of Immunotherapy Company Deploying Novel Insights Into Dendritic Cell Biology, With $53M Series A
Atp Launches Adendra Therapeutics, A New Kind Of Immunotherapy Company Deploying Novel Insights Into Dendritic Cell Biology, With $53M Series A
12/07/21, 3:30 AM
Location
new yorkMoney raised
$53 million
Industry
financial services
Round Type
series a
ATP (Apple Tree Partners), a leader in life sciences venture capital, today announced the launch of Adendra Therapeutics Ltd. ("Adendra"), a company that will discover and develop treatments for cancers and autoimmune diseases by applying new insights into regulation of adaptive immune responses by dendritic cells. Adendra is funded with a $53 (£40) million Series A investment from ATP and founded by ATP as a spin-out of breakthrough biology conducted at the Francis Crick Institute in London in the lab of immunologist Caetano Reis e Sousa, D.Phil., whose research on ways in which dendritic cells orchestrate immune responses to cell death has been published in leading scientific journals.
Company Info
Location
new york, new york, united states
Additional Info
Founded in 1999, ATP is a leader in life sciences venture capital, with $2.65 billion in committed capital and offices in New York, London, San Francisco, and Cambridge, MA. ATP creates companies starting at various stages, from pre-IP ideas to asset spinouts, investing in them from seed stage through IPO and beyond. The core of ATP's strategy is to provide flexible capital and access to a world-class team of venture partners and EIRs, to build sustainable, research-driven enterprises that deliver therapeutics to improve human lives. For more information, visit www.appletreepartners.com.